Welcome to our dedicated page for TELA Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TELA Bio, Inc. filings document a commercial-stage medical technology business centered on soft-tissue reconstruction and the OviTex product portfolio for hernia repair and abdominal wall reconstruction. Form 8-K reports cover operating and financial results, revenue updates, Regulation FD disclosures, material agreements, debt and equity capital structure, and other material events tied to the company's medical technology operations.
Proxy materials and governance-related 8-Ks record board composition, director appointments and resignations, executive compensation matters, stockholder meeting proposals, inducement and equity-award practices, and Nasdaq listing-compliance disclosures for TELA common stock listed on the Nasdaq Global Market.
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports amended beneficial ownership of TELA Bio, Inc. common stock as of June 30, 2026. They may be deemed to beneficially own 5,794,114 shares, representing 12.94% of the outstanding common stock, held by funds and separately managed accounts advised by Nantahala.
Each reporting person has shared voting and dispositive power over 5,794,114 shares and no sole voting or dispositive power. Blackwell Partners LLC – Series A, a fund advised by Nantahala, has the right to receive or direct dividends and sale proceeds on more than five percent of the outstanding common stock reported.
SilverArc Capital Management, LLC and Devesh Gandhi report their beneficial ownership in TELA BIO, INC. Class A Common Stock on an amended Schedule 13G (Amendment No. 2). As of June 30, 2026, they beneficially owned 2,137,201 shares of Class A Common Stock, representing 4.8% of the class. They report no sole voting or dispositive power over these shares, but shared voting and shared dispositive power over all 2,137,201 shares. The filing indicates ownership of 5 percent or less of the outstanding Class A Common Stock.
TELA Bio, Inc. amended a prior report to detail the separation agreement with former Chief Executive Officer Antony Koblish, whose role ended on August 3, 2026. As of the August 7, 2026 effective date, Mr. Koblish receives accrued salary through his separation date and eligibility to elect continued health, dental and vision coverage through August 31, 2026.
He is entitled to 12 months of base salary, paid in regular payroll installments, and up to 12 months of COBRA premiums paid by the company if he timely elects coverage. All of his outstanding equity awards immediately vest as of the effective date, and his stock option exercise period is extended until the earlier of December 31, 2027 or each option’s normal expiration, subject to earlier termination on a change in control. His performance stock units may still vest based on revenue and gross margin goals through December 31, 2026, or at target if a change in control occurs by that date. In return, he provides a general release and waiver of claims.
TELA Bio, Inc., a commercial-stage medtech company focused on soft-tissue reconstruction, reported relatively flat revenue but widening losses for the quarter and six months ended June 30, 2026. Quarterly revenue was $19.3 million, down 4% year over year, and first-half revenue was $38.4 million, down 1%. OviTex hernia products grew in unit volume, but OviTex PRS plastic/reconstructive products declined and U.S. price/mix shifted toward smaller, lower-priced units.
Net loss increased to $11.3 million for the quarter and $23.5 million year-to-date, driven partly by higher interest expense after refinancing into a $60 million Perceptive term loan. Gross margin improved to 72% in the quarter. Cash and cash equivalents fell to $30.4 million, and the company reported stockholders’ deficit of $15.9 million.
Management disclosed that forecasts indicate probable noncompliance with minimum revenue covenants under the Perceptive Credit Agreement within 12 months and highlighted sensitivity to a $5 million minimum liquidity covenant. These factors, combined ongoing operating losses and limited liquidity to repay accelerated debt, led to a conclusion that substantial doubt exists about the company’s ability to continue as a going concern. Management is pursuing covenant waivers or amendments, revenue initiatives, and cost reductions while also maintaining a $50 million at-the-market equity program with no sales to date.
SilverArc Capital Management, LLC and Devesh Gandhi reported beneficial ownership of Class A Common Stock of TELA BIO, INC. They collectively hold 2,137,201 shares, representing 4.8% of the class. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported.
Both reporting persons disclose ownership of 5 percent or less of the class. SilverArc is organized in Delaware and Gandhi is a U.S. citizen, with their principal business office in Boston, Massachusetts.
TELA Bio reported second quarter 2026 revenue of $19.3 million, down 4% from $20.2 million a year earlier, as OviTex PRS volumes declined and price/mix pressures in hernia procedures persisted. Gross profit was $13.9 million, with gross margin improving to 72% from 70%, helped by a tariff refund and lower excess and obsolete inventory charges.
Operating expenses held flat at $23.2 million, but net loss widened to $11.3 million from $9.9 million. As of June 30, 2026, cash and cash equivalents were $30.4 million, long-term debt was $56.1 million, and stockholders’ equity shifted to a $15.9 million deficit from positive $6.3 million at year-end 2025. Management withdrew full-year 2026 revenue guidance while the new CEO reviews strategy, citing the need to improve PRS performance, accelerate hernia market share gains, and take decisive actions to extend the cash runway and align costs with the top line. Hernia unit volumes grew 12% year over year, and international revenue continued to increase.
TELA Bio, Inc. reports that Chief Executive Officer Heather C. Getz received new equity awards on August 3, 2026. She was granted 500,000 restricted stock units of common stock, increasing her holdings to 505,000 shares. She also received options for 1,365,000 shares at a $0.74 exercise price and 1,005,000 shares at $0.90, both expiring August 3, 2036. The RSUs vest in four equal annual installments beginning August 3, 2027, and each option vests 25% on that date with the remaining 75% vesting monthly over 36 months, subject to continued service.
TELA Bio, Inc. director and Chief Executive Officer Heather C. Getz filed an initial statement of beneficial ownership, reporting 5000.0000 shares of Common Stock held directly as of 2026-08-03. The filing also references an Exhibit 24 Power of Attorney authorizing certain SEC filing actions.
TELA Bio, Inc. made a leadership change on August 3, 2026, when the board determined that Antony Koblish would no longer serve as chief executive officer and principal executive officer and he resigned from the board, with his departure treated as a termination without cause and a separation agreement to be finalized and disclosed later.
The board appointed Heather Getz as chief executive officer, principal executive officer and a Class II director, and entered into an employment agreement providing a $650,000 base salary, a target annual bonus equal to 100% of salary, severance of 12 months salary and benefits if terminated without Cause or for Good Reason, enhanced to 18 months salary, 150% of target bonus and accelerated equity vesting during a Change of Control Period. As inducement equity, she received options for 1,365,000 shares at market price, premium options for 1,005,000 shares at the higher of $0.90 or a 15% premium, and 500,000 RSUs, plus potential top-up grants so that her Initial and Top-Up Grants equal 5% of outstanding shares after future equity financings.
Plovanic William J. reported acquisition or exercise transactions in this Form 4 filing.
TELA Bio, Inc. director William J. Plovanic received a grant of 20,930 shares of common stock, valued at $0.785 per share, as compensation. The shares were issued in lieu of cash under the company’s Amended and Restated Non-Employee Director Compensation Policy and are fully vested, bringing his direct holdings to 44,530 shares.